Dicerna Pharmaceuticals this week announced the publication of data by company researchers and collaborators demonstrating the potential therapeutic benefit of knocking down a key cancer target using RNAi.
Dicerna Pharmaceuticals this week announced that partner Kyowa Hakko Kirin has decided to advance a second cancer drug candidate into formal development as part of the companies' ongoing alliance.
The move has triggered a $5 million milestone payment to Dicerna.
Dicerna Pharmaceuticals said this week that it has reached another milestone in its collaboration with Kyowa Hakko Kirin after the Japanese pharmaceutical firm “recognized the successful achievement of an in vivo activity milestone” for a second oncology drug candidate.
LAS VEGAS — Dicerna Pharmaceuticals has selected a target and delivery technology for its first drug candidate, and remains on track to meet its previously stated goal of filing an investigational new drug application by the end of 2013, a company official disclosed this week.